Lisata Therapeutics Inc. (LSTA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lisata Therapeutics Inc. (LSTA) has a cash flow conversion efficiency ratio of -0.195x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.34 Million) by net assets ($17.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Lisata Therapeutics Inc. (LSTA) balance sheet quality index to measure how much of total assets are equity-financed.
Lisata Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (1993–2024)
This chart illustrates how Lisata Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Lisata Therapeutics Inc. (LSTA) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Lisata Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lisata Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Allmed Solutions Ltd
TA:ALMD
|
-0.241x |
|
Grande Asset Hotels and Property Public Company Limited
BK:GRAND
|
-0.037x |
|
Canstar Resources Inc
V:ROX
|
-1.680x |
|
Techno Medical Public Company Limited
BK:TM
|
0.212x |
|
Jewett-Cameron Trading Company Ltd.
NASDAQ:JCTC
|
-0.034x |
|
Stelar Metals Ltd
AU:SLB
|
-0.051x |
|
Swift Networks Group Ltd
AU:SW1
|
-0.012x |
|
ASKOLL EVA S.P.A.
F:736
|
N/A |
Annual Cash Flow Conversion Efficiency for Lisata Therapeutics Inc. (1993–2024)
The table below shows the annual cash flow conversion efficiency of Lisata Therapeutics Inc. from 1993 to 2024. For the full company profile with market capitalisation and key ratios, see Lisata Therapeutics Inc. market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $29.32 Million | $-19.36 Million | -0.660x | -57.85% |
| 2023-12-31 | $47.89 Million | $-20.03 Million | -0.418x | -31.04% |
| 2022-12-31 | $66.32 Million | $-21.17 Million | -0.319x | -32.01% |
| 2021-12-31 | $92.00 Million | $-22.25 Million | -0.242x | +11.64% |
| 2020-12-31 | $32.24 Million | $-8.82 Million | -0.274x | +70.21% |
| 2019-12-31 | $20.55 Million | $-18.88 Million | -0.919x | -72.17% |
| 2018-12-31 | $37.45 Million | $-19.99 Million | -0.534x | -28.29% |
| 2017-12-31 | $50.19 Million | $-20.88 Million | -0.416x | +92.85% |
| 2016-12-31 | $4.07 Million | $-23.67 Million | -5.820x | -245.19% |
| 2015-12-31 | $23.28 Million | $-39.26 Million | -1.686x | -108.80% |
| 2014-12-31 | $58.07 Million | $-46.90 Million | -0.808x | -84.81% |
| 2013-12-31 | $62.03 Million | $-27.10 Million | -0.437x | -3.52% |
| 2012-12-31 | $32.82 Million | $-13.85 Million | -0.422x | -61.61% |
| 2011-12-31 | $80.13 Million | $-20.93 Million | -0.261x | -166.47% |
| 2010-12-31 | $86.49 Million | $-8.48 Million | -0.098x | +32.47% |
| 2009-12-31 | $59.59 Million | $-8.65 Million | -0.145x | +97.35% |
| 2008-12-31 | $863.18K | $-4.73 Million | -5.482x | -196.46% |
| 2007-12-31 | $3.32 Million | $-6.13 Million | -1.849x | +85.16% |
| 2006-12-31 | $292.11K | $-3.64 Million | -12.457x | -2814.98% |
| 2005-12-31 | $-1.82 Million | $-834.00K | 0.459x | -39.28% |
| 2004-12-31 | $-1.93 Million | $-1.46 Million | 0.756x | +11.11% |
| 2003-12-31 | $-1.50 Million | $-1.02 Million | 0.680x | +155.73% |
| 2002-12-31 | $-823.89K | $1.01 Million | -1.220x | -21.99% |
| 2001-12-31 | $373.73K | $-373.84K | -1.000x | -58.51% |
| 2000-12-31 | $3.13 Million | $-1.98 Million | -0.631x | -579.82% |
| 1999-12-31 | $3.92 Million | $-364.12K | -0.093x | -110.60% |
| 1998-12-31 | $-307.81K | $-269.60K | 0.876x | +87.60% |
| 1996-12-31 | $-651.71K | $-304.27K | 0.467x | -82.23% |
| 1995-12-31 | $-319.11K | $-838.44K | 2.627x | +807.11% |
| 1994-12-31 | $-2.90 Million | $-840.00K | 0.290x | -- |
| 1993-12-31 | $0.00 | $470.00K | x | -- |
About Lisata Therapeutics Inc.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal ca… Read more